Meng-Xue Zheng1, Yan Li2, Rong Hu3, Fei-Miao Wang4, Xiao-Mei Zhang5, Bing Guan5. 1. Ningxia Medical University, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China. 2. Department of Gynecology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China. 3. Reproductive Medicine Center, Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China. hr7424@126.com. 4. Reproductive Medicine Center, Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China. 5. Reproductive Medicine Center, Department of Obstetrics and Gynecology, Northern Jiangsu People's Hospital, Yangzhou University, Yangzhou, 225001, China.
Abstract
PURPOSE: The objective of the study was to investigate whether genetic polymorphisms of the anti-Müllerian hormone (AMH) and its specific receptor anti-Müllerian hormone type II receptor (AMHRII) were associated with the hormone disorder and phenotype of polycystic ovary syndrome (PCOS). METHODS: This case-control study included 141 PCOS patients and 123 normal women. Two polymorphisms of AMH and AMHRII and the clinical characteristics of participants such as body mass index (BMI), serum luteinizing hormone (LH), estradiol levels (E2), total testosterone levels (T), and homeostasis model assessment of insulin resistance (HOMA-IR) were analyzed with the case-control sample. Gene-gene interactions of AMH and AMHRII genes were analyzed based multifactor-dimensionality reduction method. RESULTS: A significant difference of AMH gene polymorphisms were observed in IR-PCOS women and controls. The AMH and AMHRII gene polymorphisms were not found a significant difference in non-IR-PCOS and normal groups. To IR-PCOS women, genotypes of AMH were closely related to the serum levels of LH (P = 0.000), testosterone (P = 0.000) and HOMA-IR (P = 0.038), while in the non-IR-PCOS and normal groups, no relationship was found. No impact of AMH and AMHRII gene-gene interactions was demonstrated. CONCLUSIONS: Our research suggests that the diversity of AMH genotypes in the AMH signal pathway may be connected with the susceptibility and phenotype of PCOS with insulin resistance.
PURPOSE: The objective of the study was to investigate whether genetic polymorphisms of the anti-Müllerian hormone (AMH) and its specific receptor anti-Müllerian hormone type II receptor (AMHRII) were associated with the hormone disorder and phenotype of polycystic ovary syndrome (PCOS). METHODS: This case-control study included 141 PCOS patients and 123 normal women. Two polymorphisms of AMH and AMHRII and the clinical characteristics of participants such as body mass index (BMI), serum luteinizing hormone (LH), estradiol levels (E2), total testosterone levels (T), and homeostasis model assessment of insulin resistance (HOMA-IR) were analyzed with the case-control sample. Gene-gene interactions of AMH and AMHRII genes were analyzed based multifactor-dimensionality reduction method. RESULTS: A significant difference of AMH gene polymorphisms were observed in IR-PCOS women and controls. The AMH and AMHRII gene polymorphisms were not found a significant difference in non-IR-PCOS and normal groups. To IR-PCOS women, genotypes of AMH were closely related to the serum levels of LH (P = 0.000), testosterone (P = 0.000) and HOMA-IR (P = 0.038), while in the non-IR-PCOS and normal groups, no relationship was found. No impact of AMH and AMHRII gene-gene interactions was demonstrated. CONCLUSIONS: Our research suggests that the diversity of AMH genotypes in the AMH signal pathway may be connected with the susceptibility and phenotype of PCOS with insulin resistance.
Entities:
Keywords:
Androgen; Anti-Müllerian hormone (AMH); Anti-Müllerian hormone type II receptor (AMHRII); Insulin resistance (IR); Polycystic ovary syndrome (PCOS); Polymorphisms
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Marlies E Kevenaar; Axel P N Themmen; Joop S E Laven; Barbara Sonntag; Sharon Lie Fong; André G Uitterlinden; Frank H de Jong; Huibert A P Pols; Manuela Simoni; Jenny A Visser Journal: Hum Reprod Date: 2007-03-02 Impact factor: 6.918
Authors: Marlies E Kevenaar; Joop S E Laven; Sharon Lie Fong; André G Uitterlinden; Frank H de Jong; Axel P N Themmen; Jenny A Visser Journal: J Clin Endocrinol Metab Date: 2008-01-29 Impact factor: 5.958
Authors: Danielle Hiam; Alba Moreno-Asso; Helena J Teede; Joop S E Laven; Nigel K Stepto; Lisa J Moran; Melanie Gibson-Helm Journal: J Clin Med Date: 2019-10-03 Impact factor: 4.241